WB007 / Whitecap Biosci - LARVOL DELTA

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2 | N=77 | Completed | Sponsor: Whitecap Biosciences, LLC | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2 | N=77 | Active, not recruiting | Sponsor: Whitecap Biosciences, LLC | Trial completion date: Dec 2021 ➔ Jan 2023

Trial completion date • Cardiovascular • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2; N=77; Active, not recruiting; Sponsor: Whitecap Biosciences, LLC; Recruiting ➔ Active, not recruiting; Trial completion date: Jul 2021 ➔ Dec 2021

Clinical • Enrollment closed • Trial completion date • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Whitecap Biosciences, LLC; Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Jun 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Glaucoma • Hypertension • Ophthalmology

Newly added product (clinicaltrials.gov) - P2, Glaucoma

Pipeline update